Adverum Biotechnologies, Inc.

NASDAQ (USD): Adverum Biotechnologies, Inc. (ADVM)

Last Price

4.25

Today's Change

+0.05 (1.19%)

Day's Change

4.01 - 4.37

Trading Volume

310,679

Overview

Market Cap

88 Million

Shares Outstanding

20 Million

Avg Volume

221,821

Avg Price (50 Days)

6.02

Avg Price (200 Days)

7.71

PE Ratio

-0.71

EPS

-5.95

Earnings Announcement

17-Mar-2025

Previous Close

4.20

Open

4.22

Day's Range

4.01 - 4.37

Year Range

4.01 - 29.7

Trading Volume

312,423

Price Change Highlight

1 Day Change

1.19%

5 Day Change

-4.06%

1 Month Change

-20.86%

3 Month Change

-45.02%

6 Month Change

-46.27%

Ytd Change

-11.46%

1 Year Change

-47.34%

3 Year Change

-74.24%

5 Year Change

-96.28%

10 Year Change

-99.25%

Max Change

-98.48%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment